Real-World Evidence for Control of Chronic Migraine (CM) in Patients Meeting American Headache Society (AHS) Criteria Who Received Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRPmAb) Therapy Added to OnabotulinumtoxinA Treatment

被引:0
|
作者
Blumenfeld, Andrew M. [1 ]
Frishberg, Benjamin M. [1 ]
Schim, Jack D. [1 ]
Iannone, Ashley [2 ]
Yedigarova, Larisa [3 ]
Adams, Aubrey Manack [3 ]
机构
[1] Headache Ctr Southern California, Neurol Ctr, Irvine, CA USA
[2] ICON Plc, Dublin, Ireland
[3] AbbVie Co, Allergan, Lake Bluff, IL USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
1430
引用
收藏
页数:4
相关论文
共 40 条
  • [11] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey
    TOXICON, 2022, 214 : S39 - S40
  • [12] Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
    Mechtler, Laszlo
    Saikali, Nicolas
    McVige, Jennifer
    Hughes, Olivia
    Traut, Alexandra
    Adams, Aubrey Manack
    FRONTIERS IN NEUROLOGY, 2022, 12
  • [13] Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine
    Mechtler, L.
    Saikali, N.
    McVige, J.
    Hughes, O.
    Traut, A.
    Adams, A.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 74 - 74
  • [14] Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
    Andrew M. Blumenfeld
    Benjamin M. Frishberg
    Jack D. Schim
    Ashley Iannone
    Gary Schneider
    Larisa Yedigarova
    Aubrey Manack Adams
    Pain and Therapy, 2021, 10 : 809 - 826
  • [15] Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
    Blumenfeld, Andrew M.
    Frishberg, Benjamin M.
    Schim, Jack D.
    Iannone, Ashley
    Schneider, Gary
    Yedigarova, Larisa
    Manack Adams, Aubrey
    PAIN AND THERAPY, 2021, 10 (02) : 809 - 826
  • [16] Persistence to OnabotulinumtoxinA or Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy Among Patients With Migraine: A Retrospective Cohort Study
    Talon, B.
    Charleston, L.
    Nahas-Geiger, S.
    Sullivan, C.
    Soni-Brahmbhatt, S.
    Anderson, C.
    Kymes, S.
    Regnier, S.
    HEADACHE, 2023, 63 : 151 - 151
  • [17] Persistence to OnabotulinumtoxinA or Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy Among Patients With Migraine: A Retrospective Cohort Study
    Talon, Brian
    Sullivan, Christine
    Karnik-Henry, Meghana
    Soni-Brahmbhatt, Seema
    Anderson, Carlton
    Kymes, Steven
    Regnier, Stephane A.
    NEUROLOGY, 2023, 100 (17)
  • [18] Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan
    Wang, Yen-Feng
    Yang, Fu-Chi
    Chen, Lu-An
    Chang, Ting-Yu
    Su, Hui-Chen
    Yang, Chun-Pai
    Tu, Yi-Hsien
    Tzeng, Yi-Shiang
    Chen, Shih-Pin
    Fuh, Jong-Ling
    Lai, Kuan-Lin
    Ling, Yu-Hsiang
    Chen, Wei-Ta
    Wang, Shuu-Jiun
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (09)
  • [19] Adherence and Persistence of Calcitonin Gene-Related Peptide Monoclonal Antibodies in Patients with Migraine: A Real-World Study
    Varnado, O.
    Brady, L.
    Zagar, A.
    Robles, Y.
    Hoyt, M.
    Hall, J.
    HEADACHE, 2023, 63 : 184 - 184
  • [20] Adherence and Persistence of Calcitonin Gene-Related Peptide Monoclonal Antibodies in Patients with Migraine: A Real-World Study
    Varnado, Oralee
    Brady, Brenna
    Zagar, Anthony J.
    Robles, Yvonne
    Hoyt, Margaret
    Hall, Jerry
    NEUROLOGY, 2023, 100 (17)